The in-vitro fertilization market (IVF) has grown significantly since the first successful IVF birth in 1978. According to a report by Grand View Research, the global market size was estimated at USD 23.6 billion in 2022.
The main factors driving the market growth are:
According to a report by Mordor Intelligence, the largest market is North America, followed by Europe, Asia-Pacific, Middle East and Africa, and South America.
The projected growth of the in vitro fertilization market for the next five years is expected to be influenced by various factors, such as the changing demographics and social norms, the increasing awareness and accessibility of IVF services, the rising success rate of IVF technology, and the emerging innovations in IVF procedures and devices. By the Mordor Intelligence’s report, the global IVF market size is expected to grow from USD 24.46 billion in 2023 to USD 35.60 billion by 2028, registering a CAGR of 8.2% during the forecast period (2023-2028).
In the dynamic field of MedTech, In Vitro Fertilization (IVF) stands out as an area ripe with technological innovation, thanks to significant investments and the tireless efforts of fertility clinics, doctors, and embryologists. These stakeholders are committed to providing enhanced, affordable solutions to individuals aspiring to parenthood. Recent breakthroughs in AI-powered embryo analysis, non-invasive sperm selection, and monitoring technology hold immense promise for improving success rates, enhancing accessibility, and personalizing the patient experience.
– Artificial Intelligence (AI) in IVF: AI is transforming IVF through various applications aimed at increasing the efficacy of treatments. Innovations include Vitrolife’s Embryoscope’s iDAScore, employing AI-driven Time-Lapse Monitoring (TLM) to analyze embryo development, and SiD by IVF 2.0, alongside Life Whisperer Genetics, which utilizes AI for the evaluation of euploid embryos. Cooper Fertility Solutions introduces PGTai for improved embryo assessment through AI, while LifeWhisperer’s Viability predicts pregnancy outcomes from a single image. Other notable advancements are the AlphaFold Data Base for protein structure prediction related to sperm, and MIM Fertility’s FolliScan for accurate transvaginal ultrasound follicle measurement.
– Automation of the ART process: Automation in Assisted Reproductive Technology (ART) processes is redefining IVF/ART manufacturing and distribution. Innovations include Overture Life’s development of an IVF Lab based on “biochip” technology, TMRW LifeSciences’ CryoRobot for cryostorage, and pioneering work by Conceivable, AutoIVF, and Fertilis in full IVF cycle automation and embryo quality enhancement, respectively.
– Stem Cell Treatment: Stem cell treatment represents a frontier in combating infertility, using stem cells to produce gametes or rejuvenate reproductive capabilities. Conception is at the forefront with its revolutionary Invitro Gametogenesis (IVG) technology.
– Cryopreservation: Cryopreservation technologies, spearheaded by companies like Kitazato and Vitrolife, are critical for storing gametes or embryos. Innovations like Fertil Ibérica’s SpermVD technology are enhancing sperm survival and motility post-thaw.
– Genetics/Genomics: Preimplantation genetic screening is vital for identifying chromosomal abnormalities before implantation. Key players are Illumina Inc., with its Next Generation Sequencing (NGS), and CooperGenomics, offering advanced genetic testing. This segment also highlights companies like iGenomix and Natera, leading the way in genetic analysis and non-invasive prenatal testing (NIPT).
– Sperm Selection and management: Advancements in sperm selection technologies, such as CASA by Hamilton Thorne and the Sperm Class Analyzer by Microptic, improve the efficiency and reliability of selecting the optimal sperm for fertilization. The field also enjoys innovations in microscope design, sperm quality tracking through IVF 2.0’s SiD technology, and non-invasive sperm selection methods like Examen’s SpermComet.
Other areas: The realm of IVF is also witnessing progress in microfluidics, nanorobotics, 3D printing of biomaterials, and wearables. Companies like Kitazato and Micronit are pioneering microrobots for embryo transfer and organ-on-a-chip (OOC) microdevices. Meanwhile, the development of biomaterials and advancements in microfluidics from companies like Fluigent are set to enhance IVF procedures’ efficiency and precision. Additionally, wearables from entities like Ava Women and Oura offer novel approaches to optimizing reproductive processes.
Our B2B marketplace is designed to help IVF device manufacturers easily find the right distributors in any country they choose. Our platform offers practical data on distributors worldwide, so you can quickly find and directly contact the best fit for your products. With our platform, you can unlock new markets for your IVF/fertility devices and take your business to the next level.
® FinDBest. All Rights Reserved. Supported by Gemini AI.
